Nebivolol Dose Titration
For heart failure, start nebivolol at 1.25 mg once daily and double the dose every 1-2 weeks as tolerated, targeting 10 mg once daily over a period of weeks to months. 1
Heart Failure Titration Protocol
The European Society of Cardiology guidelines provide the evidence-based titration schedule derived from the SENIORS trial 1:
- Starting dose: 1.25 mg once daily
- Incremental doses: 2.5 mg → 5 mg → 10 mg daily
- Target dose: 10 mg once daily
- Titration interval: Double the dose every 1-2 weeks if the preceding dose was well tolerated
- Timeline: Weeks to months to reach target
Pre-Titration Requirements
Before initiating nebivolol 1:
- Patient must be on background ACE inhibitor therapy (unless contraindicated)
- Patient should be relatively stable without need for IV inotropic support
- No signs of marked fluid retention
Monitoring During Titration
At each dose escalation, monitor for 1:
- Heart failure symptoms and fluid retention
- Blood pressure (hypotension)
- Heart rate (symptomatic bradycardia)
- Body weight
Managing Adverse Effects During Titration
If worsening heart failure symptoms or fluid retention occur 1:
- First increase diuretic dose or ACE inhibitor dose
- Temporarily reduce beta-blocker dose only if increasing other medications doesn't work
If hypotension develops 1:
- First reduce vasodilator doses
- Reduce beta-blocker dose only if necessary
If symptomatic bradycardia occurs 1:
- Review and reduce/discontinue other heart rate-lowering drugs (digoxin, amiodarone, diltiazem)
- Reduce beta-blocker dose only if necessary
- Discontinue only if clearly necessary
Critical principle: Always consider reintroduction and uptitration when the patient stabilizes 1.
Hypertension Titration Protocol
For hypertension, the FDA-approved dosing differs 2:
- Starting dose: 5 mg once daily (with or without food)
- Titration interval: Increase at 2-week intervals if needed
- Maximum dose: 40 mg once daily
- Note: More frequent dosing intervals are unlikely to provide additional benefit
Special Populations
Severe renal impairment (CrCl <30 mL/min) 2:
- Start at 2.5 mg once daily
- Titrate slowly as needed
Moderate hepatic impairment 2:
- Start at 2.5 mg once daily
- Titrate slowly as needed
- Avoid in severe hepatic impairment (not studied)
Elderly patients 2:
- No dose adjustment necessary
- The SENIORS trial specifically demonstrated efficacy and tolerability in patients ≥70 years 3
CYP2D6 poor metabolizers 2:
- No dose adjustment necessary
- Clinical effect and safety profile similar to extensive metabolizers
Evidence Supporting Dose-Response Relationship
The SENIORS trial demonstrated that achieving higher maintenance doses correlates with better outcomes 4:
- 10 mg dose: HR 0.75 (95% CI 0.63-0.90) vs placebo for death or CV hospitalization
- 5 mg dose: HR 0.73 (95% CI 0.52-1.02) vs placebo
- Low doses (1.25-2.5 mg): HR 0.88 (95% CI 0.64-1.20) vs placebo
- Patients unable to tolerate any dose: HR 1.95 (95% CI 1.38-2.75) - worst prognosis
This dose-response relationship emphasizes the importance of aggressive uptitration to the 10 mg target dose whenever possible 4.
Common Pitfalls to Avoid
Don't withhold or reduce doses for asymptomatic hypotension - mild BP reductions don't require dose adjustments 5
Don't discontinue for mild worsening renal function - small to moderate decreases in eGFR (up to 20%) are not associated with acute kidney injury and beta-blockers may be protective 5
Don't assume all beta-blockers are equivalent - only bisoprolol, carvedilol, and metoprolol succinate CR have proven mortality benefits in heart failure; nebivolol's evidence comes specifically from the SENIORS trial 6
Don't uptitrate too rapidly - the 1-2 week interval between dose increases allows assessment of tolerance and prevents unnecessary adverse events 1
Remember: some beta-blocker is better than no beta-blocker - if target dose cannot be achieved, maintain the highest tolerated dose 6